Picked for a well-established tolerability profile
As with all GnRH agonists, adverse events are related to hypo-estrogenism.2,3
A full list of adverse events is listed in the Prostap DCS summary of product characteristics
Picked for heritage and experience
Considerations2,3
• In order to ensure adequate ovarian suppression in pre- and perimenopausal women, administer leuprorelin for at least 6-8 weeks prior to commencement of an aromatase inhibitor and on schedule without interruption throughout aromatase inhibitor treatment to avoid rebound increases in circulating estrogens in premenopausal women
• Following chemotherapy and before commencement of leuprorelin, confirm premenopausal status by blood concentrations of estradiol and FSH, to avoid unnecessary treatment in the event of chemotherapy-induced menopause
• Following commencement of leuprorelin and prior to aromatase inhibitor treatment, confirm ovarian suppression by assessment of circulating FSH and estradiol and repeat every 3 months during combination treatment
• Discontinue aromatase inhibitors within 1 month of the last Prostap SR DCS administration and within 3 months of the last Prostap 3 DCS administration
• Check relevant safety information of co-administered products
• Assess bone mineral density before starting treatment and monitor and treat for osteoporosis when appropriate
• Risk of musculoskeletal disorders when a GnRH agonist is used in combination with either an aromatase inhibitor or tamoxifen
• Hypertension has been reported. Monitor cardiovascular risk factors, blood pressure, hyperglycaemia and diabetes regularly in premenopausal women with breast cancer receiving GnRH in combination with exemestane or tamoxifen.
• Monitor patients with depression or depression history
• Patients should notify physician if regular menstruation persists